Payment overview · 2025
General Payments
$678.42
39 reported records · 13 companies
Healthcare provider profile · identity verified
Charles Peter Lichty, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BIRMINGHAM, AL · NPI 1487627766
Verified facts
What the public records show
CMS Open Payments records show Charles Peter Lichty, M.D. received $678.42 in general payments during 2025 across 39 reported records.
PFIZER INC. accounted for 27.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $187.24 | 27.6% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $102.36 | 15.1% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.50 | 8.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $56.45 | 8.3% | 3 | 2025 |
| Melinta Therapeutics, LLC | Unresolved — no canonical attribution shown | $49.13 | 7.2% | 2 | 2025 |
| La Jolla Pharmaceutical Company | Unresolved — no canonical attribution shown | $44.51 | 6.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.93 | 6.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.17 | 4.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.37 | 4.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.26 | 3.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.53 | 2.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.92 | 2.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.05 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $678.42 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $126.13 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $114.40 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $102.36 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $88.34 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $61.11 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $61.11 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $61.11 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $60.50 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $60.50 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $56.45 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $56.45 | 3 | 2025 |
Source payment records
|
|||||
| Kimyrsa Normalized: kimyrsa |
Drug | Melinta Therapeutics, LLC | $49.13 | 2 | 2025 |
Source payment records
|
|||||
| Orbactiv Normalized: orbactiv |
Drug | Melinta Therapeutics, LLC | $49.13 | 2 | 2025 |
Source payment records
|
|||||
| Rezzayo Normalized: rezzayo |
Drug | Melinta Therapeutics, LLC | $49.13 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.93 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.17 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.37 | 2 | 2025 |
Source payment records
|
|||||
| XACDURO Normalized: xacduro |
Drug | La Jolla Pharmaceutical Company | $28.34 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.53 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| ZEVTERA Normalized: zevtera |
Drug | La Jolla Pharmaceutical Company | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $11.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 103 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 133 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 137 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
66 | 15 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
75 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
133 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
137 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
103 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 632 | 187 |
| Levothyroxine Sodium | Levothyroxine Sodium | 530 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 476 | 144 |
| Pantoprazole Sodium | Pantoprazole Sodium | 434 | 125 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 375 | 112 |
| Losartan Potassium | Losartan Potassium | 346 | 109 |
| Omeprazole | Omeprazole | 284 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 281 | 86 |
| Simvastatin | Simvastatin | 250 | 66 |
| Citalopram Hbr | Citalopram Hydrobromide | 249 | 78 |
| Lisinopril | Lisinopril | 248 | 67 |
| Zolpidem Tartrate | Zolpidem Tartrate | 213 | 45 |
| Gabapentin | Gabapentin | 194 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 55 |
| Allopurinol | Allopurinol | 180 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 62 |
| Metformin Hcl | Metformin Hcl | 160 | 49 |
| Alprazolam | Alprazolam | 156 | 39 |
| Azithromycin | Azithromycin | 151 | 126 |
| Furosemide | Furosemide | 151 | 48 |
| Potassium Chloride | Potassium Chloride | 144 | 40 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 139 | 103 |
| Meloxicam | Meloxicam | 137 | 45 |
| Ozempic | Semaglutide | 137 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 134 | 41 |
| Mounjaro | Tirzepatide | 133 | 20 |
| Clonazepam | Clonazepam | 127 | 29 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 125 | 30 |
| Carvedilol | Carvedilol | 125 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 125 | 40 |
| Trazodone Hcl | Trazodone Hcl | 124 | 40 |
| Pioglitazone Hcl | Pioglitazone Hcl | 123 | 39 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 118 | 32 |
| Montelukast Sodium | Montelukast Sodium | 111 | 34 |
| Sertraline Hcl | Sertraline Hcl | 108 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 106 | 34 |
| Lorazepam | Lorazepam | 106 | 20 |
| Eliquis | Apixaban | 103 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 29 |
| Glipizide | Glipizide | 88 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 88 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 34 |
| Alendronate Sodium | Alendronate Sodium | 81 | 21 |
| Famotidine | Famotidine | 81 | 25 |
| Fenofibrate | Fenofibrate,micronized | 81 | 20 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 78 | 16 |
| Farxiga | Dapagliflozin Propanediol | 75 | 15 |
| Jardiance | Empagliflozin | 73 | 16 |
| Celecoxib | Celecoxib | 66 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 14 |
| Synthroid | Levothyroxine Sodium | 66 | 15 |
| Atenolol | Atenolol | 64 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 17 |
| Tramadol Hcl | Tramadol Hcl | 63 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 57 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 17 |
| Clonidine Hcl | Clonidine Hcl | 55 | 17 |
| Bupropion Xl | Bupropion Hcl | 53 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 53 | 17 |
| Metformin Hcl Er | Metformin Hcl | 53 | 15 |
| Valacyclovir | Valacyclovir Hcl | 53 | 22 |
| Januvia | Sitagliptin Phosphate | 52 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 14 |
| Temazepam | Temazepam | 50 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 13 |
| Fluconazole | Fluconazole | 46 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | 26 |
| Methylprednisolone | Methylprednisolone | 46 | 38 |
| Cefdinir | Cefdinir | 43 | 37 |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 43 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 11 |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | 13 |
| Finasteride | Finasteride | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Baclofen | Baclofen | 38 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 38 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | 12 |
| Eszopiclone | Eszopiclone | 37 | suppressed |
| Glipizide Er | Glipizide | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 25 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 35 | 16 |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Levofloxacin | Levofloxacin | 32 | 28 |
| Methocarbamol | Methocarbamol | 32 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 12 |
| Linzess | Linaclotide | 31 | suppressed |
| Ezetimibe | Ezetimibe | 30 | 12 |
| Spironolactone | Spironolactone | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 20 |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 24 |
| Valsartan | Valsartan | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | 11 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 23 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Zaleplon | Zaleplon | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $678.42 · 39 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, COMIRNATY, Cologuard Collection Kit, ELIQUIS, Kimyrsa, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Orbactiv, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rezzayo, Rybelsus, SHINGRIX, UBRELVY, Veozah, XACDURO, ZAVZPRET, ZEPBOUND, ZERBAXA, ZEVTERA | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error